SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-021271
Filing Date
2023-05-11
Accepted
2023-05-11 16:18:02
Documents
105
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q atai-20230331.htm   iXBRL 10-Q 4273702
2 EX-31.1 atai-ex31_1.htm EX-31.1 18674
3 EX-31.2 atai-ex31_2.htm EX-31.2 20987
4 EX-32.1 atai-ex32_1.htm EX-32.1 11907
5 EX-32.2 atai-ex32_2.htm EX-32.2 11976
6 GRAPHIC img105938706_0.jpg GRAPHIC 873390
  Complete submission text file 0000950170-23-021271.txt   22128806

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT atai-20230331.xsd EX-101.SCH 156999
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT atai-20230331_def.xml EX-101.DEF 706725
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT atai-20230331_cal.xml EX-101.CAL 75025
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT atai-20230331_pre.xml EX-101.PRE 922914
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT atai-20230331_lab.xml EX-101.LAB 1042592
99 EXTRACTED XBRL INSTANCE DOCUMENT atai-20230331_htm.xml XML 4729514
Mailing Address 524 BROADWAY NEW YORK NY 10013
Business Address WALLSTRASSE 16 BERLIN 2M 10179 (617)-699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40493 | Film No.: 23911315
SIC: 2834 Pharmaceutical Preparations